[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of September 28",
    "summary": "Read the latest dividend updates for Dividend Champions, Contenders, and Challengers. Track changes, ex-dividend, and pay dates.",
    "url": "https://finnhub.io/api/news?id=c4a8b5db273a50fb0dccfb65fc669bab8a801736c44cfb869a3db785dd3009fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758910169,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of September 28",
      "id": 136896065,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1188013046/image_1188013046.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Read the latest dividend updates for Dividend Champions, Contenders, and Challengers. Track changes, ex-dividend, and pay dates.",
      "url": "https://finnhub.io/api/news?id=c4a8b5db273a50fb0dccfb65fc669bab8a801736c44cfb869a3db785dd3009fa"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=21660da51e8749dffb584e97eea4b97662382871cb45db56afc08ff4f92f992c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758904800,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 136925587,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=21660da51e8749dffb584e97eea4b97662382871cb45db56afc08ff4f92f992c"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices",
    "summary": "AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.",
    "url": "https://finnhub.io/api/news?id=7f79b7a66eea8b6545763363c05cf3f735dd94b66db0c61fd42e05093c052e30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758901380,
      "headline": "AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices",
      "id": 136893767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AstraZeneca said it will offer its asthma and diabetes drugs at an up to 70% discount in the U.S. ahead of a Trump administration deadline for pharmaceutical companies to cut drug prices.",
      "url": "https://finnhub.io/api/news?id=7f79b7a66eea8b6545763363c05cf3f735dd94b66db0c61fd42e05093c052e30"
    }
  },
  {
    "ts": null,
    "headline": "US, European pharma stocks steady after Trump's tariff move, Asia slips",
    "summary": "SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S.  Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments.  The conditions sort of weaken the announcement, which is probably why the market is not overly reacting, said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.",
    "url": "https://finnhub.io/api/news?id=81cc1afbda3c970156aecb3f0a49a5c39bb2c5b4269afd5e64476eefa96f0230",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758897964,
      "headline": "US, European pharma stocks steady after Trump's tariff move, Asia slips",
      "id": 136915782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S.  Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments.  The conditions sort of weaken the announcement, which is probably why the market is not overly reacting, said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.",
      "url": "https://finnhub.io/api/news?id=81cc1afbda3c970156aecb3f0a49a5c39bb2c5b4269afd5e64476eefa96f0230"
    }
  },
  {
    "ts": null,
    "headline": "MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?",
    "summary": "Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.",
    "url": "https://finnhub.io/api/news?id=cd7b1eae56c22a726ff1d8ceb6db5b596c1e1074f6c26bc32d3be4fef641810e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758894000,
      "headline": "MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?",
      "id": 136892743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.",
      "url": "https://finnhub.io/api/news?id=cd7b1eae56c22a726ff1d8ceb6db5b596c1e1074f6c26bc32d3be4fef641810e"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says",
    "summary": "The good news: There are several loopholes in Trump’s proposal that mean the impact of the new taxes may be limited.",
    "url": "https://finnhub.io/api/news?id=a1b8196a1e904d6a633763c3243a38cdc75112b8f6b4e8f666b058d2cdc24ff3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758885899,
      "headline": "Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says",
      "id": 136897113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The good news: There are several loopholes in Trump’s proposal that mean the impact of the new taxes may be limited.",
      "url": "https://finnhub.io/api/news?id=a1b8196a1e904d6a633763c3243a38cdc75112b8f6b4e8f666b058d2cdc24ff3"
    }
  },
  {
    "ts": null,
    "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
    "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
    "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758885865,
      "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
      "id": 136892883,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1645808639/image_1645808639.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
      "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741"
    }
  },
  {
    "ts": null,
    "headline": "Is pharma’s IRA pricing battle running out of steam?",
    "summary": "Despite recent court losses, the legal tides could still turn in the industry’s favor.",
    "url": "https://finnhub.io/api/news?id=f6aa2163f1c3fff410027754855b17bdfd6b031ab8367e07eb13b66d6ab1b6d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758876102,
      "headline": "Is pharma’s IRA pricing battle running out of steam?",
      "id": 136892658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Despite recent court losses, the legal tides could still turn in the industry’s favor.",
      "url": "https://finnhub.io/api/news?id=f6aa2163f1c3fff410027754855b17bdfd6b031ab8367e07eb13b66d6ab1b6d5"
    }
  },
  {
    "ts": null,
    "headline": "Trump Plans New Tariff Push With 100% Rate on Patented Drugs",
    "summary": "“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump posted on social media Thursday, without offering specifics on which producers will be impacted.  “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”",
    "url": "https://finnhub.io/api/news?id=405bb7558df757d18271ae19363d916f178b5c7324db98af9d47ec112ffd5d4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758871035,
      "headline": "Trump Plans New Tariff Push With 100% Rate on Patented Drugs",
      "id": 136890601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump posted on social media Thursday, without offering specifics on which producers will be impacted.  “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”",
      "url": "https://finnhub.io/api/news?id=405bb7558df757d18271ae19363d916f178b5c7324db98af9d47ec112ffd5d4e"
    }
  }
]